Publication:
ARL3 activation requires the co-GEF BART and effector-mediated turnover

Simple item page
dc.contributor.affiliationCRUK- Beatson Institute, Glasgow, United Kingdom, FundaciĆ³n IMDEA- Nanociencia, Campus de Cantoblanco, Madrid, Spain, Unidad Asociada de NanobiotecnologĆ­a (CNB-CSIC e IMDEA Nanociencia), Campus de Cantoblanco, Madrid, Spain, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom, Department of Chemistry, KU Leuven, Celestijnenlaan, Heverlee, Belgium, Stanford University School of Medicine, United Statesen
dc.contributor.affiliation000000041762408X
dc.contributor.authorElMaghloob Y.
dc.contributor.authorSot, BegoƱa
dc.contributor.authorMcIlwraith M.J.
dc.contributor.authorGarcia E.
dc.contributor.authorYelland T.
dc.contributor.authorIsmail S.
dc.contributor.authorPfeffer S.R.
dc.date.accessioned2021-02-18T08:52:46Z
dc.date.available2021-02-18T08:52:46Z
dc.date.issued2021
dc.format.mimetypeapplication/pdfen
dc.identifier.doi10.7554/eLife.64624en
dc.identifier.urihttp://hdl.handle.net/20.500.12614/2522
dc.issue.numbere64624en
dc.journal.titleeLifeen
dc.language.isoenen
dc.page.initial1en
dc.relation.projectIDTEMPWe thank Alfred Wittinghofer, Wim Versees and Raphael Gasper for the excellent scientific discussions. This work was supported by Cancer Research UK (CRUK core funding award A19257).
dc.rightsAtribuciĆ³n-NoComercial-SinDerivadas 3.0 EspaƱa*
dc.rightsAtribuciĆ³n-NoComercial-SinDerivadas 3.0 EspaƱa*
dc.rights.accessRightsopen accessen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titleARL3 activation requires the co-GEF BART and effector-mediated turnoveren
dc.typeresearch articleen
dc.type.hasVersionVoRen
dc.volume.number10en
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ARL3-activation-requires-the-co-GEF-BART-and-effector-mediated-turnover.pdf
Size:
3.94 MB
Format:
Adobe Portable Document Format
Download

Collections

Publications